# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Arthur Ashe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML013-SYN
- Date: 2026-04-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Vivian Tolliver, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month HIV and lipid review. **S**

## History of present illness

Mr. Ashe returns three months after his first visit, about seven months after starting antiretroviral therapy. He has missed no doses. He has had no headache, weakness, rash, fever, or chest pain. He is coaching four afternoons a week and hitting balls three times a week without angina. He has had no muscle aches on atorvastatin and ezetimibe. His blood tests were drawn this morning. He left before giving a urine sample, so the urine albumin test ordered at the last visit was not done. He feels more like himself and says that worry about his privacy comes and goes. **S**

| Element | Detail |
|---|---|
| Adherence | No missed doses |
| Activity | Coaching four afternoons a week; tennis drills without angina |
| Side effects | None |
| Urine test | Not collected this morning |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or night sweats; weight up 1.2 kg |
| Cardiovascular | Negative | No chest pain or palpitations |
| Musculoskeletal | Negative | No muscle aches |
| Neurological | Negative | No headache, seizure, or weakness |
| Psychiatric | Negative | Mood good; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium **S**
- Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/74 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 73.8 kg; BMI 21.6 kg/m². All vital signs are synthetic.

HIV-1 viral load: 0 {copies}/mL; CD4 count: 218 /uL (low); White cell count: 4.6 10*3/uL; Hemoglobin: 13.6 g/dL; Platelets: 224 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.7 mmol/L; Creatinine: 1.15 mg/dL; eGFR: 80 mL/min/1.73 m²; Glucose: 94 mg/dL; ALT: 27 U/L; Total cholesterol: 118 mg/dL; HDL cholesterol: 41 mg/dL; Triglycerides: 125 mg/dL; LDL cholesterol: 52 mg/dL; Lipoprotein(a): 24 mg/dL; Hepatitis B surface antibody: 86 m[IU]/mL. All results are synthetic.

## Change since baseline

- HIV-1 viral load: 42 {copies}/mL (high) at baseline, 0 {copies}/mL at this visit **S**
- CD4 count: 156 /uL (low) at baseline, 218 /uL (low) at this visit **S**
- White cell count: 4.2 10*3/uL at baseline, 4.6 10*3/uL at this visit **S**
- Hemoglobin: 13 g/dL (low) at baseline, 13.6 g/dL at this visit **S**
- Platelets: 198 10*3/uL at baseline, 224 10*3/uL at this visit **S**
- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.9 mmol/L at baseline, 4.7 mmol/L at this visit **S**
- Creatinine: 1.18 mg/dL at baseline, 1.15 mg/dL at this visit **S**
- eGFR: 78 mL/min/1.73 m² at baseline, 80 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 94 mg/dL at this visit **S**
- ALT: 30 U/L at baseline, 27 U/L at this visit **S**
- Total cholesterol: 158 mg/dL at baseline, 118 mg/dL at this visit **S**
- HDL cholesterol: 40 mg/dL at baseline, 41 mg/dL at this visit **S**
- Triglycerides: 150 mg/dL (high) at baseline, 125 mg/dL at this visit **S**
- LDL cholesterol: 88 mg/dL at baseline, 52 mg/dL at this visit **S**

## Immunizations given today

- Meningococcal conjugate vaccine MenACWY, dose 2 of 2 **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 73.8 kg, blood pressure 120/74 |
| Mouth | No thrush |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Neurological | Grip and fine finger movements equal on both sides |

All examination findings are synthetic. **S**

## Assessment and plan

1. **HIV infection** (B20). Viral load not detected (below 20 copies/mL): the goal of therapy is reached. CD4 count 218, above 200 for the first time. Blood count normal: hemoglobin 13.6 g/dL, white cells 4.6, platelets 224. Potassium 4.7 mmol/L and creatinine 1.15 mg/dL, stable. Hepatitis B surface antibody 86 mIU/mL: protected. He was told that once the viral load has stayed undetectable for six months, HIV is not transmitted sexually. **S**
   - Continue the same regimen.
   - Viral load, CD4 count, metabolic panel, and urine albumin at six months.
2. **Cerebral toxoplasmosis on maintenance therapy** (B58.2). No symptoms. CD4 now above 200; maintenance can stop once it has stayed above 200 for more than six months. **S**
   - Continue trimethoprim-sulfamethoxazole; reassess at the nine-month visit.
3. **Hyperlipidemia** (E78.5). LDL 52 mg/dL on atorvastatin and ezetimibe, below the goal of 55, from 88 at intake. Triglycerides 125, HDL 41. ALT 27 U/L. Lipoprotein(a) 24 mg/dL, not elevated. The recheck came 13 weeks after ezetimibe was added, one week outside the 4 to 12 week window, with no effect on care. **S**
   - Continue atorvastatin 80 mg and ezetimibe 10 mg.
   - Yearly lipid panel.
4. **Coronary artery disease after two bypass operations** (I25.10). No angina with regular vigorous exercise; blood pressure at goal. **S**
   - Continue aspirin and the chest-pain plan.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HIV-1 viral load | 4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 months | Completed today | Not detected (below 20 copies/mL), from 42 three months ago |
| Laboratory | CD4 count | Every 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ART | Completed today | 218 cells/uL, above 200 for the first time |
| Medication safety | ART adherence and drug-interaction review (antacids, calcium, iron, new medicines) | Every visit | Completed today | No missed doses; no interacting medicines |
| Laboratory | Complete blood count | Every 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ART | Completed today | Hemoglobin 13.6 g/dL, white cells 4.6, platelets 224 |
| Laboratory | Potassium, creatinine, and eGFR | 1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 months | Completed today | Potassium 4.7 mmol/L, creatinine 1.15 mg/dL, eGFR 80 |
| Laboratory | Urine albumin-to-creatinine ratio on tenofovir | At the start of tenofovir and yearly | Deferred | Ordered after the deviation recorded at the four-week visit, but the sample was not collected this morning: a second miss. Creatinine is stable, so no harm is evident. Corrective action: the urine sample is now part of the standing order for each blood draw, starting at six months |
| Laboratory | ALT | Every 6 months on ART; with symptoms on a statin | Completed today | ALT 27 U/L |
| Medication safety | Toxoplasma maintenance therapy and stopping criteria | Continue until CD4 above 200 for more than 6 months on ART with a suppressed viral load | Completed today | CD4 above 200 for the first time; continue for at least six more months |
| Medication safety | Pneumocystis prophylaxis | While CD4 below 200; stop after more than 3 months above 200 | Completed today | Covered by the maintenance dose |
| Examination | Neurological check: headache, seizure, weakness, and right-hand strength | Every visit | Completed today | No symptoms; strength equal |
| Laboratory | Hepatitis B vaccine series and antibody check | Two doses four weeks apart; surface antibody 1 to 2 months after the last dose | Completed today | Surface antibody 86 mIU/mL nine weeks after dose 2: protected |
| Self-management | Meningococcal ACWY vaccine | Two doses at least 8 weeks apart, then every 5 years | Completed today | Dose 2 given today, thirteen weeks after dose 1; booster in five years |
| Self-management | Recombinant zoster vaccine | Two doses 2 to 6 months apart, from age 18 with HIV | Completed today | Dose 1 given today |
| Self-management | Psychosocial support, disclosure on his terms, and U=U counseling | Every visit | Completed today | Worry about privacy comes and goes; U=U explained; peer support offered again |
| Survey | Depression screen (PHQ-9 or PHQ-2) | At intake, at six months, and yearly | Up to date | PHQ-9 5 at intake; mood good; next at six months |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 120/74 mmHg |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 73.8 kg, BMI 21.6; regaining weight lost during his illness |
| Self-management | Tobacco use | Every visit | Completed today | Never used tobacco |
| Medication safety | Coronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibe | Every visit | Completed today | Taking all three; no muscle aches |
| Self-management | Angina review and chest-pain plan | Every visit | Completed today | No angina with tennis drills; nitroglycerin not used |
| Laboratory | Lipid panel | 4 to 12 weeks after a change, then every 3 to 12 months; yearly when stable | Completed today | LDL 52 mg/dL, at goal; drawn 13 weeks after the change, one week outside the window, with no effect on care |
| Laboratory | Lipoprotein(a), once in adulthood | Once in adulthood | Completed today | 24 mg/dL, not elevated; no repeat needed |
| Imaging | Stress testing, coronary imaging, or echocardiography | Only with new or worsening symptoms; routine surveillance not recommended | Not indicated | No symptoms |

## Goal progress

- HIV-1 viral load not detected by the three-month visit. Outcome by 2026-04-13: Viral load not detected (below 20 copies/mL) at three months, and at six and nine months. **S**
- CD4 count above 200 cells/uL for more than six months with an undetectable viral load, so that maintenance therapy can stop safely. In progress; target 2026-10-19. **S**
- LDL cholesterol below 55 mg/dL by the three-month visit. Outcome by 2026-04-13: LDL cholesterol 52 mg/dL on atorvastatin and ezetimibe. **S**
- Hepatitis B vaccine series completed with a protective antibody level by the three-month visit. Outcome by 2026-04-13: Hepatitis B surface antibody 86 mIU/mL. **S**
- Keep blood pressure below 130/80 mmHg. In progress; target 2026-07-13. **S**

## Guideline basis

- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition), U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition), National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America
- Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024), International Antiviral Society-USA (JAMA)
- Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020), HIV Medicine Association of the Infectious Diseases Society of America (Clinical Infectious Diseases)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Six-month visit with viral load, CD4 count, metabolic panel, urine albumin, and the PHQ-9. Results by secure message. **S**
- Next scheduled visit 2026-07-13: six-month HIV and coronary disease review with depression screening. **S**
